For our analysis, we compared EZN-2208 versus topotecan or irinotecan efficacy in drug-naïve Brca1−/−;p53−/− mammary tumors that showed ABCG2 expression in tumor cell subpopulations. The gene discussed is TP53; the disease is breast cancer.